Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tc99m Sestamibi MBI for Predicting Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer
NCT02324387Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2015
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Open-label, single-arm trial of technetium-99m sestamibi in breast cancer, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Detection of Treatment Response using Molecular Breast Imaging (MBI) plus Tc99m sestamibi at 24 weeks. Started Jun 2015; status: active, not recruiting.
02
Drugs
technetium-99m sestamibi
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02324387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02324387.